Abpro and Celltrion Highlight CT-P72/ABP-102 Advances
Abpro Corporation (Nasdaq: ABP) and Celltrion, Inc. are thrilled to announce groundbreaking advancements concerning their investigational tetravalent bispecific antibody, CT-P72/ABP-102, which targets HER2 and CD3. The latest preclinical data will be presented at the Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting, which takes place soon.
Key Highlights from the Preclinical Data
The upcoming presentation features CT-P72/ABP-102, boasting an impressive selection in the Top 150 abstracts out of more than 1,300 submissions for this meeting. This selection reflects the innovative nature and promising results associated with the antibody, especially against HER2-high models.
Significant Findings
- Targeted Efficacy: The antibody demonstrates enhanced anti-tumor capabilities in HER2-high settings, particularly in tumors that are known to resist existing therapies.
- Minimized Off-Target Effects: Thanks to dual-affinity engineering, CT-P72/ABP-102 shows a marked decrease in off-target activity, significantly contributing to its safety profile.
- Potential for Wider Applications: The versatility of CT-P72/ABP-102 opens doors for clinical development concerning various HER2-positive cancers, indicating a major step forward in oncology treatment.
Future Presentation Details
Hyunkyu Choi from Celltrion will present the poster titled "CT-P72/ABP-102: A dual affinity engineered HER2/CD3 tetravalent bispecific antibody with potential to overcome therapeutic barriers in HER2 high tumors with distinct potency, safety, and selectivity" during the poster session at the SITC event.
This presentation is set for Friday, taking place from 9:00 a.m. to 6:35 p.m. in the Prince George’s ABC Ballroom, where researchers and industry leaders will have the opportunity to discuss these promising therapeutic advancements.
Collaboration Insights
In a recent statement, Miles Suk, Chief Executive Officer of Abpro, expressed strong enthusiasm for the data emerging from their collaboration with Celltrion. He highlighted the antibody's capability to foster significant anti-tumor responses in challenging environments, particularly Enhertu-resistant models.
Through their DiversImmune platform, the team has shown their commitment to developing safer, effective, and precise treatments for patients grappling with HER2-driven cancers worldwide.
Further Developments
Soo Young Lee, Executive Vice President at Celltrion, noted that the advancements observed with CT-P72/ABP-102 could redefine treatment protocols for solid tumors. The thoughtful integration of dual-affinity techniques promises to lower the risks associated with traditional immunotherapy approaches.
Both companies are poised for a robust clinical pathway, intending to submit an IND package in the near future to advance CT-P72/ABP-102 into first-in-human trials.
Conclusion: A New Era for HER2+ Cancer Therapy
The developments surrounding CT-P72/ABP-102 reflect the innovative spirit driving modern cancer therapies. As Abpro and Celltrion progress toward clinical applications, the data suggest a bright future for targeted therapies that reconcile efficacy and safety in the fight against HER2-positive cancers.
Frequently Asked Questions
What is CT-P72/ABP-102?
CT-P72/ABP-102 is a bispecific antibody that targets HER2 and CD3, developed by Abpro and Celltrion to enhance anti-tumor activity while minimizing off-target effects.
What are the key advantages of this new treatment?
The treatment showcases selective binding to tumor cells, enhanced anti-tumor activity, and a favorable safety profile, making it a promising option for HER2-positive cancers.
When will CT-P72/ABP-102 be available for clinical trials?
The companies aim to submit an Investigational New Drug (IND) application soon, with hopes to initiate first-in-human trials shortly afterward.
What is the significance of SITC 2025 in the context of this research?
SITC 2025 serves as a vital platform for presenting new findings in immunotherapy, allowing researchers and clinicians to share insights and advancements like those from CT-P72/ABP-102.
How does this therapy differ from existing treatments?
CT-P72/ABP-102 distinguishes itself with dual-affinity and tetravalent engineering, aiming to provide effective treatment in settings resistant to standard therapies while ensuring patient safety.
